WHO ICTRP trial
A clinical study of the efficacy and safety of recombinant human thrombopoietin…
ChiCTR2400081344 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400081344 |
|---|---|
| Public title | A clinical study of the efficacy and safety of recombinant human thrombopoietin (rhTPO) for secondary prevention of thrombocytopenia after chemotherapy for lymphoma |
| Scientific title | Clinical study on the efficacy and safety of recombinant human thrombopoietin in the prevention and treatment of thrombocytopenia after chemotherapy for lymphoma |
| Primary sponsor | Shanxi Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Prevention |
| Phase | 4 |
| Countries | China |
| Conditions | lymphoma |
| Interventions | test group A:The previous chemotherapy cycle (control cycle) showed chemotherapy-induced thrombocytopenia with a minimum platelet value <50×10^9/L was included in Group A. In the study cycle, which was the secondary prophylaxis cycle (the… |
| Registration date | Feb 28, 2024 |
| Target size | test group A:60;test group B:60 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: